Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.140
+0.2101.24%
Volume:2.79M
Turnover:47.74M
Market Cap:45.47B
PE:11.55
High:17.260
Open:16.780
Low:16.780
Close:16.930
52wk High:28.232
52wk Low:14.505
Shares:2.65B
HK Float Shares:535.00M
Volume Ratio:0.49
T/O Rate:0.52%
Dividend:0.45
Dividend Rate:2.63%
EPS(LYR):1.484
ROE:6.95%
ROA:1.40%
PB:0.80
PE(LYR):11.55
PS:0.91

Loading ...

Shanghai Fosun Pharma - Recently, Marketing Registration Application for Gr1803 Injection Has Been Approved with Conditions by Nmpa China

THOMSON REUTERS
·
Aug 27

Fosun Pharma Completes HK$3.587 Million Share Buyback on August 27

Stock News
·
Aug 27

Sinopharm Group Stock Rallies 1.1% in Hong Kong

Dow Jones
·
Aug 26

Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents

Deep News
·
Aug 26

Fosun Pharma Posts Flat Profit Growth in H1, Revenue Up 4.8%

MT Newswires Live
·
Aug 26

Press Release: Fosun Pharma Announces 2026 Interim Results

Dow Jones
·
Aug 25

Sinopharm Group Stock Falls 1.9% in Hong Kong

Dow Jones
·
Aug 24

Earning Preview: FOSUN PHARMA this quarter’s revenue is expected to increase by 8.56%, and institutional views are broadly bullish

Earnings Agent
·
Aug 18

Fosun Pharma Subsidiary Enters Collaboration Framework and License Agreement

Stock News
·
Aug 17

Shanghai Fosun's Unit in Collaboration with Sandoz AG on 10 Biologic Products

Reuters
·
Aug 17

Shanghai Fosun Pharmaceutical Says to Team up Sandoz on Commercialization, Development, Manufacturing of up to 10 Biologic Products

THOMSON REUTERS
·
Aug 17

Shanghai Fosun Pharmaceutical Says Unit Signs Framework Cooperation Agreement with Sandoz Ag

THOMSON REUTERS
·
Aug 17

FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD

Bulletin Express
·
Aug 13

Fosun Pharma Schedules 25 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 13

Sinopharm Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Aug 11

Fosun Pharma Secures China Approval for Two Drugs

MT Newswires Live
·
Aug 10

Fosun Pharma Subsidiary Secures NMPA Approval for Dobutamine Hydrochloride Injection

Bulletin Express
·
Aug 07

Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution

Bulletin Express
·
Aug 07

Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug

Deep News
·
Aug 07

Fosun Pharma's Dobutamine Hydrochloride Injection Receives NMPA Marketing Approval

Stock News
·
Aug 07